News & Updates

Show Multimedia Only
Novel drug helps optimize HFrEF therapy
Novel drug helps optimize HFrEF therapy
27 Apr 2022 byAudrey Abella

In individuals receiving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for heart failure with reduced ejection fraction (HFrEF), the novel potassium binder patiromer effectively reduced serum potassium levels, the DIAMOND trial suggests, thus optimizing a guideline-directed RAASi therapy for these patients.

Novel drug helps optimize HFrEF therapy
27 Apr 2022